CoChat
Sign Up
Cited by 468Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review

Singh, Inder M., Shishehbor, Mehdi H., Ansell, Benjamin J.·2007·JAMA
DOI 10.1001/jama.298.7.786
Open this paper in CoChat — free account

Abstract

Context High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is gaining substantial interest as a therapeutic target. Objectives To review the current and emerging strategies that modify high-density lipoproteins (HDLs). Data sources Systematic search of English-language literature (1965-May 2007) in MEDLINE and the Cochrane database, using the key words HDL-C and apolipoprotein A-I and the subheadings reverse cholesterol transport, CVD [cardiovascular disease] prevention and control, drug therapy, and therapy; review of presentations made at major cardiovascular meetings from 2003-2007; and review of ongoing trials from ClinicalTrials.gov and current guidelines from major cardiovascular societies. Study selection and data extraction Study selection was prioritized to identify randomized controlled trials over meta-analyses over mechanistic studies; identified studies also included proof-of-concept studies and key phase 1 through 3 trials of novel agents. Study eligibility was assessed by 2 authors; disagreements were resolved by consensus with the third. Data synthesis Of 754 studies identified, 31 randomized controlled trials met the inclusion criteria. Currently available therapeutic and lifestyle strategies, when optimized, increase HDL-C levels by 20% to 30%. While basic and small pilot studies have shown promise, proof that increasing HDL-C levels confers a reduction in major cardiovascular outcomes independent of changes in levels of low-de…

Integrity signals

Registry

Crossref · 10.1001/jama.298.7.786

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The evidence for the use of drugs that target these lipid fractions is substantially less robust than that for statin therapy.

    “However, the evidence for the use of drugs that target these lipid fractions is substantially less robust than that for statin therapy (155).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [155]

  • The evidence for the use of drugs that target HDL cholesterol and triglyceride lipid fractions is substantially less robust than that for statin therapy.

    “However, the evidence for the use of drugs that target these lipid fractions is substantially less robust than that for statin therapy (149).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [149]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singh, I. M., Shishehbor, M. H., & Ansell, B. J.
Affiliations
  • Indiana University Health (US)
  • University of California, Los Angeles (US)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2007-08-15
Volume
298
Issue
7
Pages
786
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.298.7.786
OpenAlex
W2073638666
Cited by
468
References
12
Citations by year
2026: 2 · 2025: 8 · 2024: 16 · 2023: 13 · 2022: 13 · 2021: 14 · 2020: 12 · 2019: 10 · 2018: 12 · 2017: 19 · 2016: 14 · 2015: 26 · 2014: 19 · 2013: 41 · 2012: 29
FWCI
53.58
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD049091)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
HDL cholesterol, apolipoprotein A-I, reverse cholesterol transport, cardiovascular disease prevention, HDL metabolism, HDL-targeted therapy, lifestyle modification, cardiovascular risk factors, cholesterol-lowering drugs
MeSH terms
Anticholesteremic Agents, Biological Transport, Cardiovascular Diseases, Humans, Lipoproteins, HDL, Cholesterol, HDL, Macrophages, Risk Factors, Apolipoprotein A-I, Risk Reduction Behavior, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review